Curaleaf (OTCMKTS:CURLF) Stock Rating Lowered by Zacks Research
by Michael Walen · The Markets DailyCuraleaf (OTCMKTS:CURLF – Get Free Report) was downgraded by investment analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a research note issued on Tuesday, Zacks reports.
A number of other brokerages have also recently issued reports on CURLF. UBS Group set a $6.00 price objective on Curaleaf in a report on Monday, October 5th. Citigroup reaffirmed a “buy” rating on shares of Curaleaf in a research report on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $6.00.
View Our Latest Research Report on CURLF
Curaleaf Stock Performance
OTCMKTS CURLF opened at $8.56 on Tuesday. The stock has a market cap of $2.00 billion, a PE ratio of -65.84 and a beta of 1.55. The company has a debt-to-equity ratio of 1.06, a quick ratio of 0.73 and a current ratio of 1.52. The firm has a 50-day moving average of $9.91 and a 200-day moving average of $8.68. Curaleaf has a 52-week low of $5.40 and a 52-week high of $15.15.
Curaleaf (OTCMKTS:CURLF – Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The company reported $0.05 EPS for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.25. The business had revenue of $340.10 million for the quarter, compared to analyst estimates of $332.00 million. Curaleaf had a negative net margin of 2.62% and a negative return on equity of 0.88%. On average, sell-side analysts anticipate that Curaleaf will post 0.01 EPS for the current year.
Curaleaf Company Profile
Curaleaf Holdings, Inc is a cannabis company that cultivates, processes, manufactures and sells cannabis products. Through its retail dispensaries and wholesale operations, the company offers flower, pre-rolls, vaporizers, edibles, concentrates, tinctures and other cannabis-derived products for medical and adult-use markets, where permitted by law.
Curaleaf markets products under brands that include Curaleaf, Select and Grassroots. Its business is primarily focused on the United States, where it operates a network of cultivation and processing facilities, dispensaries and distribution operations across multiple state-regulated cannabis markets.